Expansion Study of Orally Administered NX-019 in Patients
with Advanced, EGFR Mutant Cancer
The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with Advanced,
EGFR Mutant Cancer for a study. The purpose of this study is to learn about the safety, tolerance and effectiveness of the study drug, NX-019, at different doses to see what effects (good and bad) it has on you and your cancer. In this study, different doses of NX-019 will be given to study subjects to determine the recommended dose for treating your cancer safely.
If you are enrolled in part 1 of the study (up to approximately 84 subjects), your dose will be assigned by your study doctor depending on when you enter the study. In the dose expansion part of the study (part 2), the dose or doses of NX-019 determined as safe in part 1 of the study will be given to up to approximately 174 subjects. There will be multiple groups, composed of approximately 29 subjects, depending on the type of cancer they have and the dose given. You may or may not benefit as a result of your participation in this study. However, this study may also help doctors learn things that can help other people in the future.
You will be contacted approximately every 3 months for up to 2 years after your last dose of study drug by phone, e-mail or during clinic visits to ask you about how you are feeling, the status and severity of your disease, and any anti-cancer therapies you are receiving.
Additional information found here: https://www.clinicaltrials.gov/study/NCT05514496
For questions, contact:
uvacancertrials@hscmail.mcc.virginia.edu
No Compensation